DK1636261T3 - Thrombopoietinproteiner med forbedrede egenskaber - Google Patents

Thrombopoietinproteiner med forbedrede egenskaber

Info

Publication number: DK1636261T3
Authority: DK; Denmark
Prior art keywords: tpo; improved; thrombopoietin; proteins; improved properties
Prior art date: 2003-06-26

Application number

DK04740298T

Other languages

Danish (da)

English (en)

Inventor

Matthew Baker

John Watkins

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-26

Filing date

2004-06-25

Publication date

2007-11-12

2004-06-25 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2007-11-12 Application granted granted Critical

2007-11-12 Publication of DK1636261T3 publication Critical patent/DK1636261T3/da

Links

102000036693 Thrombopoietin Human genes 0.000 title abstract 5
108010041111 Thrombopoietin Proteins 0.000 title abstract 5
102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
101000799461 Homo sapiens Thrombopoietin Proteins 0.000 abstract 2
241000282412 Homo Species 0.000 abstract 1
101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 abstract 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 abstract 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
108020001507 fusion proteins Proteins 0.000 abstract 1
102000053400 human TPO Human genes 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK04740298T 2003-06-26 2004-06-25 Thrombopoietinproteiner med forbedrede egenskaber DK1636261T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03014331		2003-06-26
PCT/EP2004/006887 WO2005000891A2 (en)	2003-06-26	2004-06-25	Thrombopoietin proteins with improved properties

Publications (1)

Publication Number	Publication Date
DK1636261T3 true DK1636261T3 (da)	2007-11-12

Family

ID=33547598

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04740298T DK1636261T3 (da)	2003-06-26	2004-06-25	Thrombopoietinproteiner med forbedrede egenskaber

Country Status (9)

Country	Link
US (1)	US7541439B2 (de)
EP (1)	EP1636261B1 (de)
AT (1)	ATE368687T1 (de)
DE (1)	DE602004007924T2 (de)
DK (1)	DK1636261T3 (de)
ES (1)	ES2289528T3 (de)
PL (1)	PL1636261T3 (de)
PT (1)	PT1636261E (de)
WO (1)	WO2005000891A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007098547A1 (en) *	2006-03-01	2007-09-07	Apollo Life Sciences Limited	A molecule and chimeric molecules thereof
GB0710529D0 (en)	2007-06-01	2007-07-11	Circassia Ltd	Vaccine
WO2009014835A2 (en) *	2007-06-21	2009-01-29	Angelica Therapeutics, Inc.	Modified toxins
EA023303B1 (ru)	2007-08-15	2016-05-31	Сиркейшиа Лимитед	Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение
EP2268297A4 (de) *	2008-02-29	2011-11-16	Angelica Therapeutics Inc	Modifizierte toxine
KR101040396B1 (ko) *	2009-01-20	2011-06-09	한올바이오파마주식회사	변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
CN105073781A (zh)	2013-01-11	2015-11-18	加州生物医学研究所	牛融合抗体
HK1220376A1 (zh)	2013-03-15	2017-05-05	Angelica Therapeutics, Inc.	修饰的毒素
AU2015269210A1 (en) *	2014-06-06	2016-12-08	The California Institute For Biomedical Research	Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6284471B1 (en) *	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6238890B1 (en) *	1994-02-18	2001-05-29	Washington University	Single chain forms of the glycoprotein hormone quartet
US5879673A (en) *	1996-01-25	1999-03-09	Genentech, Inc.	Administration of thrombopoietin on a single day only
US6458563B1 (en) *	1996-06-26	2002-10-01	Emory University	Modified factor VIII
EP1364011A2 (de) *	2001-02-26	2003-11-26	MERCK PATENT GmbH	Modifiziertes thrombopoietin mit reduzierter immunogenität
ATE542137T1 (de) *	2001-12-04	2012-02-15	Merck Patent Gmbh	Immunocytokine mit modulierter selektivität
WO2003104263A2 (en) *	2002-05-01	2003-12-18	Genencor International, Inc.	Cytokines and cytokine receptors with reduced immunogenicity

2004
- 2004-06-25 PL PL04740298T patent/PL1636261T3/pl unknown
- 2004-06-25 DK DK04740298T patent/DK1636261T3/da active
- 2004-06-25 EP EP04740298A patent/EP1636261B1/de not_active Expired - Lifetime
- 2004-06-25 AT AT04740298T patent/ATE368687T1/de not_active IP Right Cessation
- 2004-06-25 ES ES04740298T patent/ES2289528T3/es not_active Expired - Lifetime
- 2004-06-25 US US10/561,097 patent/US7541439B2/en not_active Expired - Fee Related
- 2004-06-25 DE DE602004007924T patent/DE602004007924T2/de not_active Expired - Fee Related
- 2004-06-25 PT PT04740298T patent/PT1636261E/pt unknown
- 2004-06-25 WO PCT/EP2004/006887 patent/WO2005000891A2/en not_active Ceased

Also Published As

Publication number	Publication date
US7541439B2 (en)	2009-06-02
ES2289528T3 (es)	2008-02-01
PT1636261E (pt)	2007-11-08
DE602004007924D1 (de)	2007-09-13
ATE368687T1 (de)	2007-08-15
US20060160995A1 (en)	2006-07-20
WO2005000891A2 (en)	2005-01-06
DE602004007924T2 (de)	2008-04-10
PL1636261T3 (pl)	2007-12-31
WO2005000891A3 (en)	2005-04-21
EP1636261A2 (de)	2006-03-22
EP1636261B1 (de)	2007-08-01

Similar Documents

Publication	Publication Date	Title
DE602004011770D1 (de)	2008-03-27	Fusionsproteine
ATE548388T1 (de)	2012-03-15	An den interleukin-4-rezeptor bindende antikörper
MXPA05008704A (es)	2005-10-05	Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
WO2003099771A3 (en)	2004-04-01	Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DK1368060T3 (da)	2010-08-30	HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DE60032486D1 (de)	2007-02-01	Prion protein peptide und deren verwendung
WO2006121610A3 (en)	2007-01-25	Personal care compositions and methods for their use
DK2229440T3 (da)	2013-12-09	Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
ATE368687T1 (de)	2007-08-15	Thrombopoietinproteine mit verbesserten eigenschaften
DK1687267T3 (da)	2012-01-23	Modificeret MscL-proteinkanal
EP1544214A4 (de)	2007-03-28	NICHT-NEUTRALISIERENDE ANTI-aPC-ANTIKÖRPER
WO2004113386A3 (en)	2005-10-06	Modified hirudin proteins and t-cell epitopes in hirudin
TW200724679A (en)	2007-07-01	Treatment of disease using an improved regulated expression system
EA200600314A1 (ru)	2006-06-30	Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
TW200716749A (en)	2007-05-01	Interferon-beta gene therapy using an improved, regulated expression system
ATE328082T1 (de)	2006-06-15	Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2005035564A3 (en)	2005-11-24	Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EA200700346A1 (ru)	2007-10-26	Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2006110367A3 (en)	2006-12-21	Methods and compositions for mycoplasma toxins
DE59911103D1 (de)	2004-12-23	ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1)
CY1113344T1 (el)	2016-06-22	Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων